Cargando…

Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital

Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pannier, Judith, Nass, Norbert, Yaakoub, Mohamad-Kamal, Stelzner, Florian Michael Maria, Veit, Susann, Kalomoiri, Margarita, Yassine, Mahdi, Behre, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956015/
https://www.ncbi.nlm.nih.gov/pubmed/36826353
http://dx.doi.org/10.3390/idr15010013
_version_ 1784894489004867584
author Pannier, Judith
Nass, Norbert
Yaakoub, Mohamad-Kamal
Stelzner, Florian Michael Maria
Veit, Susann
Kalomoiri, Margarita
Yassine, Mahdi
Behre, Gerhard
author_facet Pannier, Judith
Nass, Norbert
Yaakoub, Mohamad-Kamal
Stelzner, Florian Michael Maria
Veit, Susann
Kalomoiri, Margarita
Yassine, Mahdi
Behre, Gerhard
author_sort Pannier, Judith
collection PubMed
description Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab/Imdevimab or Etesevimab/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy. Results: Both groups showed a comparable spectrum of risk factors. Due to the late hospitalization of control patients, a higher frequency of severe symptoms, such as fever, dyspnea, syncope and lower viral load, were observed. CRP and leukocytes counts were also higher in the untreated group. Most importantly, hospitalization time was significantly shorter and the number of deaths was also lower in the treated group. Conclusions: Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths.
format Online
Article
Text
id pubmed-9956015
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99560152023-02-25 Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital Pannier, Judith Nass, Norbert Yaakoub, Mohamad-Kamal Stelzner, Florian Michael Maria Veit, Susann Kalomoiri, Margarita Yassine, Mahdi Behre, Gerhard Infect Dis Rep Communication Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab/Imdevimab or Etesevimab/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy. Results: Both groups showed a comparable spectrum of risk factors. Due to the late hospitalization of control patients, a higher frequency of severe symptoms, such as fever, dyspnea, syncope and lower viral load, were observed. CRP and leukocytes counts were also higher in the untreated group. Most importantly, hospitalization time was significantly shorter and the number of deaths was also lower in the treated group. Conclusions: Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths. MDPI 2023-02-20 /pmc/articles/PMC9956015/ /pubmed/36826353 http://dx.doi.org/10.3390/idr15010013 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Pannier, Judith
Nass, Norbert
Yaakoub, Mohamad-Kamal
Stelzner, Florian Michael Maria
Veit, Susann
Kalomoiri, Margarita
Yassine, Mahdi
Behre, Gerhard
Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title_full Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title_fullStr Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title_full_unstemmed Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title_short Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
title_sort monoclonal antibody therapy for covid-19: a retrospective observational study at a regional hospital
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956015/
https://www.ncbi.nlm.nih.gov/pubmed/36826353
http://dx.doi.org/10.3390/idr15010013
work_keys_str_mv AT pannierjudith monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT nassnorbert monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT yaakoubmohamadkamal monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT stelznerflorianmichaelmaria monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT veitsusann monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT kalomoirimargarita monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT yassinemahdi monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital
AT behregerhard monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital